Two Paths for the Development of Chinese Pharmaceutical Enterprises

If a formula is used to summarize the model of China's innovative drugs, it roughly looks like this: Returned scientists with their own projects + venture capital + CRO
.

At present, China's innovative drugs are booming
.

But is this prosperous fire a false fire? Different people may have different answers

Two modes

Two modes

The growth path of Chinese pharmaceutical companies can often be summarized into two types: For conventional biotech, this path is license in + CRO + VC
.

This model was pioneered by Zai Lab-instead of looking for innovative drug products directly from the source in the laboratory, but buying and buying externally

Companies that do innovative drugs and generic drugs have their own advantages and disadvantages because of the different growth soils
.

Innovative drugs could not be profitable in the early stage, and the risks were extremely high, and they were dubbed "Russian roulette"

Imitate

Imitate

On October 26, Huiyu Pharmaceuticals, a tumor drug company that exploded in the first batch of centralized procurement, officially landed on the Science and Technology Innovation Board.
Among the "big generic drugs" that everyone thinks, some transformations were disclosed in its prospectus.
Innovation details: The company's innovative drug team has nearly 100 people, and it is still growing rapidly, including 41 masters, 19 doctors, and 8 returnees.
The ratio of masters and doctors exceeds 60%, and the leader graduated from Cambridge, Harvard, and Peking University.
And other well-known universities around the world
.

Established in 2010, Huiyu Pharmaceuticals has actually been low-key making innovative drugs.

Go slowly and go far

Go slowly and go far

It is the generic drugs that determine the basic health of a country, not the innovative drugs
.

Because medical insurance needs to control costs, compared with expensive original research drugs, cheap domestic generic drugs can reduce the pressure of medical insurance, and can also alleviate the pressure of ordinary people to see a doctor

In fact, similar to the centralized drug procurement that China has vigorously promoted in the past two years, all countries will use administrative means to intervene in generic and innovative drugs, encouraging pharmaceutical companies to imitate drugs that have been on the market for a period of time, speed up market competition, and lower drug prices
.

Because if everyone takes innovative drugs, no economy can afford it

end

end

The U.
S.
medical GDP accounts for 17% of the country, and it is basically the country with the highest medical and medical expenses in the mainstream economy, not one of them
.

Therefore, the innovative drug research and development industry is a paradise in the true sense, but not every American can see a doctor normally.